Thomas F Gajewski
University of Chicago
H-index: 113
North America-United States
Top articles of Thomas F Gajewski
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Genetic elimination of β-catenin using a doxycycline-regulated GEM model fails to restore checkpoint blockade efficacy due to persistent M2-like macrophages | Cancer Research | Alexandra Cabanov Ruxandra Tonea Jason Shapiro Anna Martinez Yuanyuan Zha | 2024/3/22 |
Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy | Cell Reports | Andrea Ziblat Brendan L Horton Emily F Higgs Ken Hatogai Anna Martinez | 2024/5/28 |
Neutralizing GDF-15 can overcome anti-PD-(L) 1 resistance in late-stage cancer | Ignacio Melero María de Miguel Luken Guillermo de Velasco Elena Garralda Juan Martin Liberal | 2024/3/7 | |
Beta-catenin inhibitors in cancer immunotherapy | 2024/4/2 | ||
Synergistic innate immune activation and anti-tumor immunity through combined STING and TLR4 stimulation | bioRxiv | Emily F Higgs Thomas F Gajewski | 2024 |
Methods and compositions related to t-cell activity | 2023/10/31 | ||
Decr2 regulates tumor cell ferroptosis and immunotherapy efficacy | Cancer Research | Shuyin Li Jason Shapiro Hardik Shah Emily F Higgs Lishi Xie | 2024/3/22 |
Targeting murine or human KLRG1 exerts potent anti-tumor efficacy involving both CD8T cells and NK cells | Cancer Research | Tyler A Jones Stephen Sinicrope Kei Yasuda Jan Pinkas Thomas F Gajewski | 2024/3/22 |
Association between rheumatic autoantibodies and immune-related adverse events | The Oncologist | Kristen Mathias Sherin Rouhani Daniel Olson Anne R Bass Thomas F Gajewski | 2023/5/1 |
945 Dendritic cell-intrinsic PTPN22 negatively regulates anti-tumor immunity and impacts anti-PD-L1 efficacy | Santiago Acero Bedoya Emily Higgs Anna Martinez Thomas Gajewski | 2023/11/1 | |
Insights from a Rapidly Implemented COVID-19 Biobank Using Electronic Consent and Informatics Tools | Biopreservation and Biobanking | Emily F Higgs Blake A Flood Athalia R Pyzer Sherin J Rouhani Jonathan A Trujillo | 2023/4/1 |
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition | European Journal of Cancer | Robert Ferguson Vylyny Chat Leah Morales Danny Simpson Kelsey R Monson | 2023/8/1 |
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas | Journal for immunotherapy of cancer | Andrew L Coveler David C Smith Tycel Phillips Brendan D Curti Sanjay Goel | 2023 |
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy) | Journal of Translational Medicine | Paolo A Ascierto Sanjiv S Agarwala Christian Blank Corrado Caracò Richard D Carvajal | 2022/9/4 |
Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma | Journal of Clinical Oncology | Jason A Chesney Antoni Ribas Georgina V Long John M Kirkwood Reinhard Dummer | 2023/1/1 |
Methods and compositions for pkc-delta inhibition and cancer immunotherapy | 2023/5/11 | ||
Tissue-resident memory T cells in immune-related adverse events: friend or foe? | Oncoimmunology | Robin Reschke Thomas F Gajewski | 2023/12/31 |
Microbiome biomarkers immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof | 2023/5/2 | ||
Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment | 2023/1/31 | ||
CXCL9 and CXCL10 bring the heat to tumors | Robin Reschke Thomas F Gajewski | 2022/7/22 |
